Register for our free email digests:
Division of Shire PLC
Latest From Dyax Corp.
With Haegarda holding a convenience edge over Cinryze for HAE prophylaxis, Shire now has data showing that SHP616 also offers significant prevention of HAE attacks. How ‘616 fits into Shire’s overall HAE strategy is unclear.
Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.
Neurotrope's novel bryostatin treatment for Alzheimer's, AstraZeneca's durvalumab in bladder cancer, and Actelion’s antibiotic cadazolid are among a raft of therapies scheduled for major data read-outs or approval decisions in Q2 2017. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at some crucial drug displays likely over the next three months.
CSL Behring’s long-acting subcutaneous C1 inhibitor formulation, CSL830, has confirmed its efficacy for the prevention of hereditary angioedema (HAE) attacks, and is expected to be introduced this year, giving it initial traction in what could become a crowded sector.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Shire PLC
- Senior Management
Gustav A Christensen, Pres. & CEO
George Migausky, EVP, CFO
Burt Adelman , MD, EVP, R&D & CMO
Todd Bazemore, EVP, Chief Commercial Officer
- Contact Info
Phone: (617) 225-2500
55 Network Dr.
Burlington, MA 01803
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.